Asundexian Phase 3 AF Study Halted for Lack of Efficacy

The phase 3 OCEANIC-AF trial of the factor XI inhibitor asundexian (Bayer) has been stopped early owing to inferior efficacy vs apixaban in preventing stroke and systemic embolism in patients with AF.

Related Keywords

Boston ,Massachusetts ,United States ,North Carolina ,Safina ,Attikír ,Greece ,Noacs Doacs ,Christian Rommel ,Manesh Patel ,Global Head Of Research ,Duke Clinical Research Institute ,Medscape Cardiology ,Global Head ,Christian Ruff ,Atrial Fibrillation ,F Atrial Fibrillation ,Anticoagulation Therapy ,Anticoagulant ,Anticoagulation ,Embolism ,Thromboembolism ,Stroke ,Erebrovascular Accident ,Va Cerebrovascular Accident ,Antithrombotics ,Anti Thrombotics ,Antithrombotic Therapy ,Antithrombotic Agents ,Hemorrhage ,Bleeding ,Ischemic Stroke ,Monoclonal Antibody ,Etuximab ,Ituximab ,Transient Ischemic Attack ,Cia ,Biologic Therapy ,